Related Experiment Video
Updated: Aug 24, 2025
07:24
Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
Published on: April 8, 2013
24.4K
[SGLT2 inhibitors in acute decompensated heart failure, what do we know?]
A E Lapteva1, S N Nasonova1, I V Zhirov1,2
1Chazov National Medical Research Center of Cardiology.
Terapevticheskii Arkhiv
|October 26, 2022
Summary
Early use of SGLT2 inhibitors may improve renal function in acute decompensated heart failure patients. This review synthesizes evidence on their effects on treatment response and kidney recovery.
Area of Science:
- Cardiology
- Nephrology
- Pharmacology
Context:
- Growing global prevalence of heart failure (HF).
- Acute decompensated heart failure (ADHF) linked to poor prognosis and target organ damage.
- Limited understanding of early interventions for renal function in ADHF.
Purpose:
- To review current evidence on Sodium-glucose co-transporter 2 (SGLT2) inhibitors in ADHF.
- To assess the impact of early SGLT2 inhibitor administration on renal function.
- To evaluate potential improvements in treatment response and kidney recovery.
Summary:
- Systematic literature search (2018-2021) in Web of Science, Scopus, PubMed/MEDLINE.
- Analysis focused on SGLT2 inhibitors' effects in ADHF patients.
- Investigated outcomes related to renal function and treatment efficacy.
Impact:
- Informs clinical practice regarding SGLT2 inhibitors in ADHF.
- Highlights potential for improved renal outcomes in heart failure patients.
- Guides future research on cardiorenal interactions and therapeutic strategies.
Related Concept Videos
01:30Heart Failure V: Medical Management
19
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
19
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
487
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
487
01:26Heart Failure Drugs: Inotropic Agents
682
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
682
01:22Heart Failure Drugs: Diuretics
454
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
454
01:22Heart Failure VI: Adjunct Therapies
25
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
25
01:22Heart Failure Drugs: β-Blockers
415
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
415